# Retroviral RLI/4-1 BBL and RLI/FLT3L Combination Immunomodulatory Gene Therapy for Glioblastoma

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $95,027

## Abstract

PROJECT SUMMARY/ABSTRACT
This proposed project is within the scope of R01NS123808. There are no changes to the Project
Summary/Narrative of the Parent Award. A brief description of the Parent Grant Specific Aims is provided
within the Research and Career Plan.

## Key facts

- **NIH application ID:** 10740288
- **Project number:** 3R01NS123808-01A1S1
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Manish Aghi
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $95,027
- **Award type:** 3
- **Project period:** 2023-02-15 → 2023-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10740288

## Citation

> US National Institutes of Health, RePORTER application 10740288, Retroviral RLI/4-1 BBL and RLI/FLT3L Combination Immunomodulatory Gene Therapy for Glioblastoma (3R01NS123808-01A1S1). Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/grant/nih/10740288. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*